论文部分内容阅读
目的:评价3种化疗方案治疗非霍奇金淋巴瘤(NHL)的成本-效果。方法:文献报道对68例确诊的NHL患者随机分为吡柔比星(THP)组、表柔比里(E-ADM)组和多柔比星(ADM)组,采用CHOP标准化疗方案,其他联合用药环磷酰胺、长春新碱、泼尼松的用法和用量相同,观察疗效及不良反应,采用药物经济学的成本-效果分析法进行回顾性分析评价。结果:3组总有效率(82．6%,86．4%和82．6%)比较无显著差异(P＞0．05),THP组不良反应发生率显著低于其他两组。成本-效果分析结果显示3种方案成本效果比(C/E)分别为42．94．36．04,9．84元。结论:ADM组方案治疗NHL较为合理、经济。
Objectives: To evaluate the cost-effectiveness of three chemotherapy regimens in the treatment of non-Hodgkin’s lymphoma (NHL). Methods: A total of 68 patients with NHL were randomly divided into three groups: THP group, E-ADM group and ADM group. CHOP standard chemotherapy and other Combination of cyclophosphamide, vincristine, prednisone use and dosage the same, observe the efficacy and adverse reactions, using cost-effectiveness analysis of drug economics retrospective analysis and evaluation. Results: The total effective rate (82.6%, 86.4%, 82.6%) in the three groups showed no significant difference (P> 0.05). The incidence of adverse reactions in the THP group was significantly lower than the other two groups. The cost-effectiveness analysis showed that the cost-effectiveness ratios (C / E) of the three schemes were 42.94.36.04 and 9.84 yuan respectively. Conclusion: The ADM regimen is more reasonable and economical for the treatment of NHL.